KEEP UP WITH THE LATEST IN INDUSTRY NEWS!
From news about new medicines, pharmacy business insights, and the pharmaceutical industry in general—this is your source!
DrugTopics articles
- Siloed Systems Hinder Patient Care May 2, 2024Collaboration between health system specialty pharmacies and manufacturers can benefit patients in the long run.
- Weight-Loss Drugs Fuel Rise in US Prescription Spending May 2, 2024The rise of weight-loss drugs has overtaken the US prescription drug market and significantly increased spending from 2022 to 2023.
- CGM Use Linked to Improved Diabetic Retinopathy Outcomes in T1D May 2, 2024The current study highlights the potential benefit of incorporating continuous glucose monitor (CGM) data into eye care assessments for patients with type 1 diabetes (T1D).
- Hurdles In Access: Costly Switch Studies Block Wider Biosimilar Use May 2, 2024Addressing requirements around FDA interchangeability designations can increase the adoption of biosimilar substitutions at the pharmacy level.
- Expert: Biosimilar Legislation Making Moves in the Right Direction May 2, 2024A recent bill introduced to Congress is intended to prevent product hopping, a practice that extends exclusivity and hinders the adoption of biosimilar therapies.
- Distributors Play a Role in Patient Access Programs May 2, 2024Distributors can help manufacturers create patient access programs that reduce costs, copays, and co-insurance.
- Incentives Drive Provider, Patient Biosimilar Adoption May 1, 2024One notable incentive includes the launch of biosimilars at both low- and high wholesale acquisition costs.
- NCPA Says AI Can Help Pharmacies Optimize Cash Pricing May 1, 2024The organization has renewed its recommendation of Prescryptive Health’s artificial intelligence pricing system, stating it can help independent pharmacies stay competitive.
- FDA Approves Second Formulation of Humira Biosimilar Cyltezo May 1, 2024According to Michael Osso, president and chief executive officer of the Crohn’s & Colitis Foundation, “the flexibility of having multiple biosimilar formulations to choose from is important to support broader patient access to biologic medicine.”
- UnitedHealth CEO Testifies Before Congress on Change Healthcare Cyberattack May 1, 2024In a testimony to the Senate Finance Committee, Andrew Witty discussed what led to the February Change Healthcare cyberattack and the organization’s response.
Pharmacy Times articles
- Expert: Pharmacists Have Vital Role in Multiple Myeloma Treatment May 2, 2024The vice president of pharmacy operations at American Oncology Network says that pharmacists can contribute by educating patients and offering resources for support and treatment adherence.
- Expert Discusses Breaking Down Silos in Pharmacy Industry Partnerships May 2, 2024Elizabeth Cherry discusses the need to break down silos between manufacturers and health systems specialty pharmacies through more transparent collaboration to better serve patients.
- NABP Report Explores How Illegal Online Sellers Exploit Consumer Demand for Weight Loss Drugs May 2, 2024This class of drugs, including semaglutide, liraglutide, and tirzepatide, is used to treat type 2 diabetes and obesity.
- NABP Announces 2024 Leadership Award Recipients May 2, 2024Each year, the Association presents awards to individuals who have worked with unwavering dedication to ensure NABP’s continued service to the regulation of pharmacy practice and to the state boards of pharmacy in protecting public health.
- Change Healthcare Cyberattack Still Harming Independent Pharmacies, NCPA Says May 2, 2024Attack must lead to strong reforms of massive middlemen
- Expert Discusses Payment Models for Cell and Gene Therapies May 2, 2024Joe DePinto discusses innovative payment models like value-based agreements and warranties for cell and gene therapies
- Compounded, Counterfeit Semaglutide Poses Severe Risk to Patients May 2, 2024Novo Nordisk and Eli Lilly have spoken out against the use of their GLP-1 medications for cosmetic weight loss, emphasizing the proper use of their medications.
- Biologics for Severe Asthma Present Opportunities for Pharmacists May 2, 2024Drug therapy workups may reveal candidates for immune therapy and provide chance for interventions.
- US Preventive Services Task Force Recommends Breast Cancer Screenings Begin at Age 40 May 2, 2024The screenings should be conducted every other year, beginning at age 40 and continuing through age 74, according to the new recommendation.
- FDA Grants Fast Track Designation to Eneboparatide for Treatment of Patients With Hypoparathyroidism May 2, 2024Currently, the treatment is being evaluated in the phase 3 CALYPSO study to further prove the safety and efficacy in patients with hypoparathyroidism.
Helping You Navigate the Returns Process!
Pedigree Statement
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with it’s clients…
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with its clients. This is to ensure that the reverse distribution portion of the supply chain that we service keeps its functionality and integrity for our customers and the public.
Several pedigree and distribution level issues have been raised in the industry. Discounted, indigent-pricing, short dated, bulk purchase, secondary distribution, or DSCSA non-compliant sales could affect the credit available for a product based on a manufacturers determination. We ask that you do not return these products for credit as they are not eligible in most cases. Flash Returns LLC may choose to dispose of these on the pharmacies behalf at no charge if the cost is low relative to the return. Most customers purchasing products from reputable wholesalers will not encounter these issues, however all pharmacies are asked to acknowledge our policy on pedigree and legitimacy of product here and by signing the PSA before a return is initiated.
Some manufacturers may require proof the price paid for a product and what wholesaler distributed the product. Issues causing triggering this could be: bulk or large quantities of single items or lots, or products purchased speculatively. In some cases we may request invoices from the customer to ensure Flash Returns or manufacturer policy is being met. If none are available or if the information isn’t accepted by the manufacturer it could cause the return to be non-returnable.
Flash Returns, LLC cannot guarantee or be liable for the value or credit for products that were purchased outside of manufacturer accepted distribution channels. This could include products: purchased from a wholesaler that is not an approved vendor, products not purchased directly from a particular manufacturer, purchased on a speculative basis, diverted or counterfeit products, foreign products, and any product purchased on a non-returnable basis, including short-dated product purchased at discounted pricing.
At any time, Flash Returns, LLC or a manufacturer may require invoices or pedigree information demonstrating proof of purchase. If product has been shipped by Flash Returns, LLC or the Customer to a manufacturer or their agent, Flash Returns, LLC cannot guarantee or facilitate the return of product to the Customer. Manufacturers reverse the right to destroy product they deem not credit worthy or suspect. Manufacturers agreeing to return product to customers will do so at the customers expense. Flash Returns, LLC shall not be responsible for reimbursing a Customer for such product.
If Customer is unable to have product returned within 21 days, product is subject to be destroyed without any payment or credit issued to Customer. In any dispute, failure by Customer to provide invoices for a product or pedigree if requested shall release Flash Returns, LLC from any and all liability of products involved in dispute including the full value of the product. More information on drug pedigrees is available on the FDA website at:
Pedigree Statement
P: 833.553.5274
E: SignUp@FlashReturns.com